Positive T Cell Responses but Limited Tumor Killing: What to Investigate Next
A positive peptide-response assay and weak tumor-cell killing are not necessarily contradictory. They can measure different steps in the immune response. First identify where recognition or function may be lost, then choose a targeted follow-up experiment.
First Confirm What "Positive" Means
An IFN-γ ELISpot signal, an activation-marker change, and a peptide–MHC multimer-positive population do not describe the same biology. Check the responding population, stimulus, denominator, and whether the assay was run directly ex vivo or after in vitro expansion. A bulk PBMC signal does not automatically identify cytotoxic CD8 T cells.
Also compare the actual conditions of the recognition and killing assays. Differences in donor source, HLA context, activation history, timing, or cell quality can create an apparent mismatch without implying failure of the candidate antigen.
Locate the Missing Evidence
| Observation | Question to investigate | Useful next comparison |
|---|---|---|
| Peptide-positive, tumor-negative recognition | Does the tumor naturally process and display the target in the relevant HLA context? | Review target expression, HLA compatibility, and appropriate peptide-pulsed versus unmodified target controls. |
| Recognition detected, little tumor death | Are the responding cells able to execute the required effector function? | Combine a tumor-specific death readout with an appropriate effector-function assessment and reference condition. |
| Bulk viability changes without clear killing | Is the signal coming from tumor cells or immune cells? | Add compartment-resolved imaging, gating, or an orthogonal endpoint. |
| Good reference activity, poor activity in a suppressive setting | Does a defined inhibitory condition reduce the relevant function? | Use controlled suppression and intervention comparisons, including direct toxicity and stimulation controls. |
Check the Target Before Increasing Stimulation
Synthetic peptide loading can bypass antigen processing and create a recognition condition that an unmodified tumor does not reproduce. Source-gene expression, mutation presence, HLA expression, and naturally displayed peptide are different evidence layers. Confirm the relevant facts rather than assuming that a positive prediction or peptide assay settles the tumor-recognition question.
A negative peptide-detection result also needs context: sample amount, analytical coverage, and sensitivity can limit detection. The aim is to resolve a specific uncertainty, not to assign a universal rejection rule from one assay.
Distinguish Effector Limitations from Model Limitations
Weak killing can reflect insufficient competent effectors, an unsuitable observation window, limited access through the culture matrix, or a target/readout configuration with little dynamic range. A reference killing condition and relevant viability measurements help establish whether the model can answer the question.
If immune suppression is the hypothesis, measure its functional effect. Treg abundance or checkpoint-marker expression alone is insufficient to establish suppression or exhaustion. An intervention-associated increase in a signal may reflect direct stimulation, altered cell numbers, or toxicity to suppressor cells; companion controls are needed before calling it functional rescue.
Choose One Follow-Up That Changes the Decision
- Uncertain natural presentation: prioritize target and presentation evidence rather than repeating a peptide-response assay.
- Uncertain responding population: characterize the relevant subset or function with a suitable assay.
- Uncertain tumor death: improve the compartment-specific endpoint and reference controls.
- Defined suppressive mechanism: design a controlled perturbation with a prespecified response metric.
Study context: recent tumor-recognition and immunopeptidome research supports separating antigen availability, recognition, and functional activity. The sequence here is a troubleshooting framework, not a promise that any one experiment will reveal the cause.
Frequently Asked Questions
Should a peptide-positive candidate be discarded if killing is weak?
Not solely on that mismatch. First establish the target-recognition context and whether the killing model performed as intended.
Does higher IFN-γ guarantee stronger cytotoxicity?
No. Cytokine production and tumor-cell killing are distinct endpoints. Their relationship depends on the responding cells and experimental configuration.
References
1. Li Z, et al. Cancer Immunology, Immunotherapy. 2024;73:164. doi:10.1007/s00262-024-03749-8.
2. Kraemer AI, et al. Nature Cancer. 2023;4:608–628. doi:10.1038/s43018-023-00548-5.
Connect the Signal to the Next Experiment
T cell response testing, tumor–immune co-culture assays, and functional suppression studies address different parts of this question. A project can focus on the evidence that is currently missing.
Discuss Your Results